



(51) International Patent Classification:

A61M 15/00 (2006.01) *B05B 1/00* (2006.01)
A61M 15/08 (2006.01)

(21) International Application Number:

PCT/EP2011/005118

(22) International Filing Date:

12 October 2011 (12.10.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/392,223 12 October 2010 (12.10.2010) US

(71) Applicants (for all designated States except US): **IVAX PHARMACEUTICALS IRELAND** [IE/IE]; Unit 301, Industrial Park, Waterford (IE). **TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC.** [US/US]; 425 Privet Road, Horsham, PA 19044 (US). **IVAX RESEARCH, LLC** [US/US]; 425 Privet Road, Horsham, PA 19044 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WALSH, Declan** [IE/IE]; The Green, Gowran, Co. Kilkenny (IE). **ZENG,**

Xian-Ming [GB/US]; Golden Glades, 74 NW 176 Street, Miami, FL 33169-5043 (US). **LY, Jade** [US/US]; Golden Glades, 74 NW 176 Street, Miami, FL 33169-5043 (US). **MORALES, Armando** [US/US]; Golden Glades, 74 NW 176 Street, Miami, FL 33169-5043 (US).

(74) Agent: **COTTAM, David, William**; Teva Europe Patent Department, Field House, Station Approach, Harlow CM20 2EW, Essex (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD,

[Continued on next page]

(54) Title: NASAL SPRAY DEVICE




Fig. 1

(57) Abstract: This invention relates to a nasal spray device (1) for the delivery of a pharmaceutical formulation to the nasal cavity in metered doses. The device comprises: a pressurised aerosol canister (3) including a vial (4) containing a pharmaceutical formulation comprising an active ingredient, a propellant and, optionally, a co-solvent, the aerosol canister further including a metering valve (6) having a valve stem (8); and an actuator (2) for the aerosol canister, the actuator including a stem block (11) having a receptacle into which the valve stem of metering valve of the aerosol canister is received and axially located and being displaceable relative to the vial of the aerosol canister to actuate the metering valve of the aerosol canister, a sump (15) extending below the receptacle, the stem block further defining a discharge orifice (19) for the pharmaceutical formulation and a transfer channel (13) through which a dispensed dose of the pharmaceutical formulation is able to pass from the sump to the discharge orifice. The actuator further comprises a delivery outlet (12) for the aerosol plume, the discharge orifice being arranged to direct the aerosol plume through the delivery outlet, and wherein the device is adapted to produce an aerosol plume for a dispensed dose having a spray force value no greater than 40 mN measured at a distance of 30 mm from the discharge orifice. Use of the term formulation encompasses both solution and suspension formulations.



RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*